U.S. markets closed
  • S&P 500

    4,134.94
    -28.32 (-0.68%)
     
  • Dow 30

    33,821.30
    -256.33 (-0.75%)
     
  • Nasdaq

    13,786.27
    -128.50 (-0.92%)
     
  • Russell 2000

    2,188.21
    -43.79 (-1.96%)
     
  • Crude Oil

    62.61
    -0.77 (-1.21%)
     
  • Gold

    1,779.20
    +8.60 (+0.49%)
     
  • Silver

    25.88
    +0.04 (+0.15%)
     
  • EUR/USD

    1.2038
    -0.0003 (-0.02%)
     
  • 10-Yr Bond

    1.5620
    -0.0390 (-2.44%)
     
  • GBP/USD

    1.3939
    -0.0045 (-0.32%)
     
  • USD/JPY

    108.0980
    -0.0520 (-0.05%)
     
  • BTC-USD

    56,810.15
    +893.73 (+1.60%)
     
  • CMC Crypto 200

    1,289.82
    +55.40 (+4.49%)
     
  • FTSE 100

    6,859.87
    -140.21 (-2.00%)
     
  • Nikkei 225

    29,100.38
    -584.99 (-1.97%)
     

Akari Therapeutics' PASylated Nomacopan Shows Promising Action In Animal Studies

  • Oops!
    Something went wrong.
    Please try again later.
Vandana Singh
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Akari Therapeutics Plc (NASDAQ: AKTXannounces new data from PASylated nomacopan published in the journal CELLS.

  • In a non-infectious allergic uveitis animal model, PAS-nomacopan reduced VEGF by more than 50% compared to saline control, equivalent to the inhibition caused by an anti-VEGF antibody.

  • Separately, Akari recently completed a preclinical study in which intravitreally injected PAS-nomacopan was compared to Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Eyelea, an FDA-approved treatment for wet AMD.

  • PAS-nomacopan injected once during the 16-day treatment period was equivalent to Eyelea in reducing neo-vascularisation.

  • The company says that PAS-nomacopan was significantly more effective in reducing retinal inflammation than the anti-VEGF antibody.

  • PAS-nomacopan's optimal dose interval to be used in clinical trials is yet to be determined.

  • Price Action: AKTX shares are 0.58% higher at $3.48 in market trading hours on the last check Thursday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.